Recombinant Mouse Mapk3 Protein, Myc/DDK-tagged
|Product Overview :||Purified recombinant protein of mouse full-length mitogen-activated protein kinase 3 (Mapk3), with C-terminal MYC/DDK tag, expressed in HEK293T cells.|
- Gene Information
- Related Products
|Description :||Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC); as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.|
|Molecular Mass :||43.5 kDa|
|Purity :||> 80% as determined by SDS-PAGE and Coomassie blue staining|
|Stability :||Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.|
|Storage :||Store at -80 centigrade after receiving vials.|
|Concentration :||>50 μg/mL as determined by microplate BCA method|
|Storage Buffer :||25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.|
|Gene Name :||Mapk3 mitogen-activated protein kinase 3 [ Mus musculus (house mouse) ]|
|Official Symbol :||Mapk3|
|Synonyms :||MAPK3; mitogen-activated protein kinase 3; MAP kinase 3; p44 MAP kinase; pp42/MAP kinase; insulin-stimulated MAP2 kinase; extracellular signal-regulated kinase 1; microtubule-associated protein 2 kinase; p44; Erk1; Ert2; Mnk1; Erk-1; Esrk1; Prkm3; Mtap2k; p44erk1; p44mapk|
|Gene ID :||26417|
|mRNA Refseq :||NM_011952|
|Protein Refseq :||NP_036082|
|UniProt ID :||Q63844|
|◆ Recombinant Protein|
|MAPK3-3230R||Recombinant Rat MAPK3 Protein, His (Fc)-Avi-tagged||+Inquiry|
|MAPK3-1363H||Recombinant Human MAPK3 Protein, His (Fc)-Avi-tagged||+Inquiry|
|MAPK3-061H||Recombinant Human MAPK3 Protein, MYC/DDK-tagged, C13 and N15-labeled||+Inquiry|
|MAPK3-307H||Active Recombinant Human MAPK3 Protein||+Inquiry|
|MAPK3-1082H||Recombinant Human MAPK3 Protein (A2-P379), Tag Free||+Inquiry|
|MAPK3-4494HCL||Recombinant Human MAPK3 293 Cell Lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (7)Ask a question
Dysregulation of MAPK3 signaling has been implicated in the pathogenesis of several diseases. Aberrant activation of MAPK3 is associated with cancer development and progression, as it promotes cell proliferation and survival. MAPK3 signaling is also involved in cardiovascular diseases, contributing to vascular remodeling and hypertrophy. In neurodegenerative diseases, dysregulated MAPK3 activity contributes to neuronal dysfunction and apoptosis.
Future research in MAPK3 aims to elucidate the intricate signaling network and identify novel regulatory mechanisms. Understanding the crosstalk between MAPK3 and other signaling pathways will be crucial for developing targeted therapies. Additionally, exploring the role of MAPK3 isoforms in different cellular contexts and disease states will provide valuable insights. Furthermore, the development of more specific and potent inhibitors with reduced toxicity profiles is a focus for future therapeutic interventions.
MAPK3, also known as ERK1 (Extracellular Signal-Regulated Kinase 1), is a serine/threonine kinase involved in cell signaling pathways. It consists of 379 amino acids and exhibits a conserved catalytic domain. MAPK3 plays a crucial role in regulating cell proliferation, differentiation, and survival by phosphorylating downstream targets such as transcription factors and other kinases.
MAPK3 signaling exerts its effects through phosphorylation of downstream targets. It phosphorylates various transcription factors, including ELK1 and c-Fos, leading to changes in gene expression. MAPK3 also phosphorylates other kinases, such as p90RSK, which further propagate the signal to regulate cellular processes like cell cycle progression, apoptosis, and differentiation.
One challenge is the potential for off-target effects when targeting MAPK3, as it is involved in multiple signaling pathways. Additionally, resistance to MAPK3 inhibitors can emerge due to compensatory signaling mechanisms and genetic alterations. Another challenge lies in achieving selective inhibition of specific MAPK3 isoforms without affecting other closely related kinases.
The activity of MAPK3 is tightly regulated by various mechanisms. Activation of MAPK3 involves dual phosphorylation of threonine and tyrosine residues by upstream kinases. Conversely, dephosphorylation by phosphatases can inactivate MAPK3. Additionally, scaffolding proteins and interacting partners can modulate its activity by facilitating or inhibiting its phosphorylation or by regulating its subcellular localization.
Inhibition of MAPK3 activity or downstream effectors represents a potential therapeutic approach. Small molecule inhibitors targeting MAPK3 kinase activity, such as U0126 and PD98059, have been developed. Monoclonal antibodies against MAPK3 or its downstream effectors are also being investigated. Combination therapies targeting multiple components of the MAPK3 signaling pathway are being explored to enhance efficacy and overcome resistance.
Customer Reviews (3)Write a review
Exemplary precision and unblemished dependability render it my most cherished research ally. -
Presenting exceptional reliability and stability, the experimental reagent establishes a robust foundation for my experiments. -
Exquisitely crafted packaging design adds convenience to the usage of this protein reagent and exudes a sense of sophistication. -
Ask a Question for All Mapk3 Products
Required fields are marked with *
My Review for All Mapk3 Products
Required fields are marked with *